Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy.

ABSTRACT: Circulating tumor DNA (ctDNA) correlates with tumor burden and provides early detection of treatment response and tumor genetic alterations in breast cancer (BC). In this study, we aimed to identify genetic alterations during the process of tumor clonal evolution and examine if ctDNA level well indicated clinical response to neoadjuvant chemotherapy (NAC) and BC recurrence. We performed targeted ultra-deep sequencing of plasma DNAs, matched germline DNAs and tumor DNAs from locally advanced BC patients. Serial plasma DNAs were collected at diagnosis, after the 1^st cycle of NAC and after curative surgery. For the target enrichment, we designed RNA baits covering a total of ∼202kb regions of the human genome including a total of 82 cancer-related genes. For ctDNA, 15 serial sample

SUBMITTER: Kim JY 

PROVIDER: S-EPMC5689695 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature